Thus, despite the fact that leptin has the potential to be a therapeutic drug for neurological diseases through different molecular mechanisms and a target for combination therapy, it is not a clinical biomarker for neurological diseases before a clear mechanism is explored. This evidence concerns the gene LEP and nervous system disorder.